| Title |
Docetaxel
|
|---|---|
| Published in |
Drugs, September 2012
|
| DOI | 10.2165/00003495-200565170-00007 |
| Pubmed ID | |
| Authors |
Katherine A. Lyseng-Williamson, Caroline Fenton |
| Abstract |
Docetaxel (Taxotere), a cytotoxic taxane, is an antimicrotubule agent effective in the treatment of patients with breast cancer. The clinical profile of docetaxel as an effective cytotoxic agent in the treatment of metastatic breast cancer is well established. As yet, no single standard regimen has been identified as optimal for the treatment of patients with metastatic breast cancer after failure of prior chemotherapy. However, the efficacy of docetaxel monotherapy administered every 3 weeks as a 1-hour infusion is similar to or better than that of doxorubicin, paclitaxel and fluorouracil plus vinorelbine, and better than that of methotrexate plus fluorouracil or mitomycin plus vinblastine. Although docetaxel is associated with neutropenia and other adverse events, its overall tolerability profile is generally acceptable in the majority of patients. Docetaxel, therefore, is an effective option in the treatment of patients with metastatic breast cancer after failure of prior chemotherapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 105 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 21 | 20% |
| Student > Ph. D. Student | 19 | 18% |
| Student > Bachelor | 15 | 14% |
| Student > Doctoral Student | 7 | 7% |
| Researcher | 6 | 6% |
| Other | 14 | 13% |
| Unknown | 25 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 16% |
| Agricultural and Biological Sciences | 17 | 16% |
| Biochemistry, Genetics and Molecular Biology | 14 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 8% |
| Engineering | 8 | 7% |
| Other | 11 | 10% |
| Unknown | 31 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2022.
All research outputs
#3,798,945
of 25,374,917 outputs
Outputs from Drugs
#536
of 3,464 outputs
Outputs of similar age
#26,902
of 189,085 outputs
Outputs of similar age from Drugs
#147
of 1,461 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,085 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 1,461 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.